Scientists found that if they break a specific 'on switch' near a gene called PCSK9 in liver cancer cells, the gene barely works anymore—meaning this switch is super important for making the gene active.
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The claim describes a direct experimental manipulation (site-directed mutation) in a controlled in vitro system (HepG2 cells) with a quantified outcome (>90% reduction). This is a classic mechanistic experiment in molecular biology where promoter-reporter assays are standard. The use of 'reduces by more than 90%' and 'critical transcriptional activator' is justified by the magnitude of effect and the specificity of the mutation targeting a known binding site. No overstatement is present because the conclusion is confined to the experimental system and directly supported by the data.
More Accurate Statement
“Mutation of the HNF1 binding site located 28 base pairs upstream of the sterol response element (SRE) in the PCSK9 promoter reduces promoter activity by more than 90% in HepG2 liver cancer cells, indicating that HNF1 is a critical transcriptional activator of PCSK9 gene expression in this cellular context.”
Context Details
Domain
medicine
Population
in_vitro
Subject
Mutation of the HNF1 binding site located 28 bp upstream of the SRE in the PCSK9 promoter
Action
reduces
Target
promoter activity by more than 90% in HepG2 liver cancer cells, indicating HNF1 is a critical transcriptional activator of PCSK9 gene expression
Intervention Details
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Evidence from Studies
Supporting (1)
Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine*
Scientists changed a specific part of the DNA in liver cancer cells that helps turn on the PCSK9 gene, and when they did, the gene’s activity dropped by over 90% — proving that this part is essential for the gene to work.